ArticleApplied microbiology and biotechnology2013
The novel antimicrobial peptide PXL150 in the local treatment of skin and soft tissue infections.
Article in Applied microbiology and biotechnology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Wound Healing: Molecular Mechanisms, Antimicrobial Peptides, and Emerging Technologies in Regenerative Medicine.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Functional characterization of Paillotin: an immune peptide regulated by the Immune deficiency (Imd) pathway with pathogen-specific roles inProceedings. Biological sciences · 2025Article
- Understanding the pathophysiology ofBurns & trauma · 2025Review
- Antimicrobial peptide-based strategies to overcome antimicrobial resistance.Archives of microbiology · 2024Review
- Screening of the Skin-Regenerative Potential of Antimicrobial Peptides: Clavanin A, Clavanin-MO, and Mastoparan-MO.International journal of molecular sciences · 2024Article
- Mimicking Nonribosomal Peptides from the Marine ActinomyceteACS infectious diseases · 2024Article
- Navigating the fungal battlefield: cysteine-rich antifungal proteins and peptides from Eurotiales.Frontiers in fungal biology · 2024Review
- Development ofMolecular pharmaceutics · 2023Article
- Biopolymer Nano-Network for Antimicrobial Peptide Protection and Local Delivery.Advanced healthcare materials · 2022Article
- Antimicrobial Peptide Mimics for Clinical Use: Does Size Matter?Frontiers in immunology · 2022Review
- Caerin 1.1 and 1.9 Peptides from Australian Tree Frog Inhibit Antibiotic-Resistant Bacteria Growth in a Murine Skin Infection Model.Microbiology spectrum · 2021Article
- Development of an Experimental Ex Vivo Wound Model to Evaluate Antimicrobial Efficacy of Topical Formulations.International journal of molecular sciences · 2021Article
- In vitro and in vivo antibacterial properties of peptide AMC-109 impregnated wound dressings and gels.The Journal of antibiotics · 2021Article
- Anti-Staphylococcal and cytotoxic activities of the short anti-microbial peptide PVP.World journal of microbiology & biotechnology · 2020Article
- Novel Antimicrobial Peptides Formulated in Chitosan Matrices are Effective Against Biofilms of Multidrug-Resistant Wound Pathogens.Military medicine · 2020Article
- Polysaccharide-Based Formulations for Healing of Skin-Related Wound Infections: Lessons from Animal Models and Clinical Trials.Biomolecules · 2019Review
- Enhancement in Site-Specific Delivery of Carvacrol against Methicillin ResistantPharmaceutics · 2019Article
- Review
- Antimicrobial Peptides and Their Therapeutic Potential for Bacterial Skin Infections and Wounds.Frontiers in pharmacology · 2018Review
- Current and Emerging Topical Antibacterials and Antiseptics: Agents, Action, and Resistance Patterns.Clinical microbiology reviews · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dramatic increase in bacterial resistance towards conventional antibiotics emphasises the importance to identify novel, more potent antimicrobial therapies. Antimicrobial peptides (AMPs) have emerged as a promising new group to be evaluated in therapeutic intervention of infectious diseases. Here we describe a novel AMP, PXL150, which demonstrates in vitro a broad spectrum microbicidal action against both Gram-positive and Gram-negative bacteria, including resistant strains. The potent microbicidal activity and broad antibacterial spectrum of PXL150 were not associated with any hemolytic activity. Staphylococcus aureus and methicillin-resistant S. aureus (MRSA) failed to develop resistance towards PXL150 during continued selection pressure. PXL150 caused a rapid depolarisation of cytoplasmic membrane of S. aureus, and dissipating membrane potential is likely one mechanism for PXL150 to kill its target bacteria. Studies in human cell lines indicated that PXL150 has anti-inflammatory properties, which might be of additional benefit. PXL150 demonstrated pronounced anti-infectious effect in an in vivo model of full thickness wounds infected with MRSA in rats and in an ex vivo model of pig skin infected with S. aureus. Subcutaneous or topical application of the peptide in rats did not lead to any adverse reactions. In conclusion, PXL150 may constitute a new therapeutic alternative for local treatment of infections, and further studies are warranted to evaluate the applicability of this AMP in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.